Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 2Myeloid 1

Conditions

Multiple Myeloma 2Neoplasms, Plasma Cell 1

Interventions

Dexamethasone 871Bortezomib 457Lenalidomide 456Cyclophosphamide 365Melphalan 272Calcium Dobesilate 263daratumumab 234pomalidomide 208carfilzomib 182fludarabine phosphate 140fludarabine 136Thalidomide 125Peripheral Blood Stem Cell Transplantation 119Filgrastim 114ixazomib 93Mycophenolic Acid 90Granulocyte Colony-Stimulating Factor 89Whole-Body Irradiation 87Busulfan 87dexamethasone acetate 86Tacrolimus 78dexamethasone 21-phosphate 74isatuximab 69Cyclosporine 68auricularum 67Prednisone 65elotuzumab 58belantamab mafodotin 57Antilymphocyte Serum 56Etoposide 53

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × SCIO-469 × Plasma cell × Clear all
NCT00095680 2010-10-22

Extension Study of the Efficacy and Safety of Oral SCIO-469 in Relapsed, Refractory Patients With Multiple Myeloma

Scios, Inc.

Phase 2 Completed
30 enrolled
Plasma cell

Multiple Myeloma

NCT00087867 2010-10-18

Study of Oral SCIO-469 in Relapsed, Refractory Patients With Multiple Myeloma

Scios, Inc.

Phase 2 Completed
62 enrolled
Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡